1. BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy. Frank Hilberg, Gerald J. Roth, Martin Krssak, Susanna Kautschitsch, Wolfgang Sommergruber, et al. Cancer Research 68, 4774, June 15, 2008. doi: 10.1158/0008-5472.CAN-07-6307
2. Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Kulimova E, Oelmann E, Bisping G, Kienast J, Mesters RM, Schwäble J, Hilberg F, Roth GJ, Munzert G, Stefanic M, Steffen B, Brandts C, M??ller-Tidow C, Kolkmeyer A, B??chner T, Serve H, Berdel WE. Mol Cancer Ther. 2006 Dec;5(12):3105-12.
3. A clinical phase I, pharmacokinetik (PK), and pharmacodynamic (PD) study of BIBF1120 in advanced cancer patients. Mross K, Baas F, Medinger M, et al. Molecular Targets and Cancer Therapeutics, 16th EORTC-NCI-AACR Symposium, September 28 to October 1, 2004, Geneva, Switzerland.
4. BIBF 1120 - a novel, small molecule triple angiokinase inhibitor: profiling as a clinical candidate for cancer therapy. Hilberg F, Tontsch-Grunt U, Colbatzky F, et al. Molecular Targets and Cancer Therapeutics, 16th EORTC-NCI-AACR Symposium, September 28 to October 1, 2004, Geneva, Switzerland.